Literature DB >> 24010918

Epidemiology and risk factors for infections in myelodysplastic syndromes.

L R Sullivan1, M A Sekeres, N K Shrestha, J P Maciejewski, R V Tiu, R Butler, S B Mossad.   

Abstract

We conducted a case-control study to describe the epidemiology and risk factors for infections requiring hospitalization in patients with myelodysplastic syndromes (MDS). Of 497 patients identified, 103 patients developed 201 episodes of infection. The probability of acquiring an infection 1 year from date of MDS diagnosis was 15% (95% confidence interval [CI] 12-18%). Patients developing infections had decreased survival compared to those who did not (P = 0.007). Significant risk factors for infection were higher risk MDS (hazard ratio [HR] = 2.7, 95% CI = 1.7-4.1, P < 0.0001), nadir absolute neutrophil count <500/mL (HR = 1.8, 95% CI = 1.2-2.7, P < 0.007), chronic obstructive pulmonary disease (HR = 2.6, 95% CI = 1.4-4.9, P < 0.003), history of other malignancy (HR 2.0, 95% CI = 1.3-3.1, P < 0.003), and autoimmune disease (HR 2.9, 95% CI = 1.4-6.0, P < 0.005). Age, nadir platelet count <20,000/mL, diabetes mellitus, and MDS treatment were not significant risk factors. Pneumonia was the most common infection, and bacteria the predominant pathogens.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  infection; myelodysplastic syndrome; risk factors

Mesh:

Year:  2013        PMID: 24010918     DOI: 10.1111/tid.12130

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  5 in total

1.  Monocyte function in patients with myelodysplastic syndrome.

Authors:  Daniel A Pollyea; Brenna R Hedin; Brian P O'Connor; Scott Alper
Journal:  J Leukoc Biol       Date:  2018-04-14       Impact factor: 4.962

2.  Risk and timing of cardiovascular death among patients with myelodysplastic syndromes.

Authors:  Andrew M Brunner; Traci M Blonquist; Gabriela S Hobbs; Philip C Amrein; Donna S Neuberg; David P Steensma; Gregory A Abel; Amir T Fathi
Journal:  Blood Adv       Date:  2017-10-18

3.  Increased prescription rate of anti-infective agents after diagnosis of myelodysplastic syndromes.

Authors:  Johanne Rozema; Mels Hoogendoorn; Iris Potma; Inge Ten Seldam; Nic J G M Veeger; Robby E Kibbelaar; Arjan A van de Loosdrecht; Eric N van Roon
Journal:  EJHaem       Date:  2022-03-25

4.  Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web-based case vignette questionnaire: The MINDSET study.

Authors:  Johanne Rozema; Eric van Roon; Lars Vogelzang; Robby Kibbelaar; Nic Veeger; Arjan van de Loosdrecht; Mels Hoogendoorn
Journal:  Eur J Haematol       Date:  2022-07-06       Impact factor: 3.674

Review 5.  Infections in Myelodysplastic Syndrome in Relation to Stage and Therapy.

Authors:  Giuseppe Leone; Livio Pagano
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-07-01       Impact factor: 3.122

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.